Raloxifene and its role in breast cancer prevention

Expert Review of Anticancer Therapy

Volumn 4, Issue 4, 2004, Pages 523-532

  Eng Wong, Jennifer ^a   Zujewski, Jo Anne ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Prevention; Raloxifene; Receptor modulator; Selective estrogen

Indexed keywords

CLOMIFENE; ESTRADIOL; ESTROGEN RECEPTOR; HISTONE DEACETYLASE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TRANSPORT; ESTROGEN RESPONSIVE ELEMENT; FLU LIKE SYNDROME; GASTROINTESTINAL ABSORPTION; HOT FLUSH; HUMAN; IN VITRO STUDY; LEG CRAMP; METASTASIS; NONHUMAN; OSTEOPOROSIS; PERIPHERAL EDEMA; REVIEW;

EID: 4444284271     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.4.523     Document Type: Review

References (94)

1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J. Clin. 54, 8-29 (2004).
2. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355, 1822 (2000).
3. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351, 1451-1467 (1998).
4. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J. Clin. Oncol. 14, 78-84 (1996).
5. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R. Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J. Gen. Intern. Med. 18, 937-947 (2003).
6. Love R, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J. Natl Cancer Inst. 86, 1534-1539 (1994).
7. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90, 1371-1388 (1998).
8. Fisher B. National Surgical Adjuvant Breast and Bowel Project breast cancer prevention trial: a reflective commentary. J. Clin. Oncol. 17, 1632-1639 (1999).
9. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J. Natl Cancer Inst. 95, 526-532 (2003).
10. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators (published erratum appears in JAMA 282 [22], 2124 [1999]). JAMA 282, 637-645 (1999).
11. Jordan VC, Koerner S. Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur. J. Cancer 11, 205-206 (1975).
12. Pyrhonen S, Valavaara R, Modig H et al. Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: a randomized double-blind, the nordic Phase III study. Br. J. Cancer 76, 270-277 (1997).
13. O'Regan RM, Cisneros A, England GM et al. Effects of the anti-estrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J. Natl Cancer Inst. 90, 1552-1558 (1998).
14. Tomas E, Kauppila A, Blanco G, Apaja-Sarkkinen M, Laatikainen T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol. Oncol. 59, 261-266 (1995).
15. Hard GC, Iatropoulos MJ, Jordan K et al. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res. 53, 4534-4541 (1993).
16. Clemens JA, Bennett DR, Black LJ, Jones CD. Effects of a new anti-estrogen, keoxifene (LY-156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci. 32, 2869-2875 (1983).
17. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary Proc. Natl Acad. Sci. USA 93, 5925-5930 (1996).
18. Pelletier G, El-Alfy M. Immunocytochemical localization of estrogen receptors α and β in the human reproductive organs. J. Clin. Endocrinol. Metab. 85, 4835-4840 (2000).
19. Critchley HO, Brenner RM, Henderson TA et al. Estrogen receptor β, but not estrogen receptor α, is present in the vascular endothelium of the human and nonhuman primate endometrium. J. Clin. Endocrinol. Metab. 86, 1370-1378 (2001).
20. Braidman IP, Hainey L, Batra G, Selby PL, Saunders PT, Hoyland JA. Localization of estrogen receptor β protein expression in adult human bone. J. Bone Miner. Res. 16, 214-220 (2001).
21. Matsuzaki S, Murakami T, Uehara S, Canis M, Sasano H, Okamura K. Expression of estrogen receptor α and β in peritoneal and ovarian endometriosis. Fertil. Steril. 75, 1198-1205 (2001).
22. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol. Pharmacol. 54, 105-112 (1998).
23. Kian Tee M, Rogatsky I. Tzagarakis-Foster C et al. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors α and β. Mol. Biol. Cell 15, 1262-1272 (2004).
24. Shiau AK, Barstad D, Loria PM et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927-937 (1998).
25. Wijayaratne AL, Nagel SC, Paige LA et al. Comparative analyses of mechanistic differences among anti-estrogens. Endocrinology 140, 5828-5840 (1999).
26. Gaub MP, Bellard M, Scheuer I, Chambon P, Sassone-Corsi P. Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. Cell 63, 1267-1276 (1990).
27. Webb P, Lopez GN, Uht RM, Kushner PJ. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin fbr the cell-specific estrogen-like effects of anti-estrogens. Mol. Endocrinol. 9, 443-456 (1995).
28. Porter W, Saville B, Hoivik D, Safe S. Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol. Endocrinol. 11, 1569-1580 (1997).
29. Stein B, Yang MX. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBPβ. Mol. Cell. Biol. 15, 4971-4979 (1995).
30. Elgort MG, Zou A, Marschke KB, Allegretto EA. Estrogen and estrogen receptor antagonists stimulate transcription from the human retinoic acid receptor-α 1 promoter via a novel sequence. Mol. Endocrinol. 10, 477-487 (1996).
31. Paech K, Webb P, Kuiper GG et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277, 1508-1510 (1997).
32. Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc. Natl Acad. Sci. USA 93, 4948-4952 (1996).
33. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270, 1354-1357 (1995).
34. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 295, 2465-2468 (2002).
35. Webb P, Nguyen P, Kushner PJ. Differential SERM effects on corepressor binding dictate ERα activity in vivo. J. Biol. Chem. 278, 6912-6920 (2003).
36. McDonnell DP, Chang CY, Norris JD. Capitalizing on the complexities of estrogen receptor pharmacology in the quest for the perfect SERM. In: Selective Estrogen Receptors Modulators. Anthony MS, Dunn BK, Sherman S (Eds), New York Academy of Sciences, NY, USA, 16-35 (2001).
37. Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe L Jr. A pharmacological review of selective oestrogen receptor modulators. Hum. Reprod. Update 6, 212-224 (2000).
38. Grese TA, Sluka JP, Bryant HU et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc. Natl Acad Sci. USA 94, 14105-14110 (1997).
39. Black LJ, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiophene derived anti-estrogen. Life Sci. 32, 1031-1036 (1983).
40. Taranta A, Brama M, Teti A et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30, 368-376 (2002).
41. Yang NN, Bryant HU, Hardikar S et al. Estrogen and raloxifene stimulate transforming growth factor-β 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology 137, 2075-2084 (1996).
42. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene (published erratum appears in Science 275[5304], 1249 [1997]). Science 273, 1222-1225 (1996).
43. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 288, 872-881 (2002).
44. Yaffe K. Estrogens, selective estrogen receptor modulators, and dementia: what is the evidence? Ann. NY Acad. Sci. 949, 215-222 (2001).
45. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 287, 591-597 (2002).
46. Henderson VW. Estrogen, cognition, and a woman's risk of Alzheimer's disease. Am. J. Med. 103, 11S-18S (1997).
47. Wu Y, Glinn MA, Ostrowski NL et al. Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats. Brain Res. 847, 98-104 (1999).
48. Bethea CL, Mirkes SJ, Su A, Michelson D. Effects of oral estrogen, raloxifene and arzoxifene on gene expression in serotonin neurons of macaques. Psychoneuroendocrinology 27, 431-445 (2002).
49. Landry M, Levesque D, Di Paolo T. Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain. Neuroendocrinology 76, 214-222 (2002).
50. de Valk-de Roo GW, Stehouwer CD, Meijer P et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler. Thromb. Vasc. Biol. 19, 2993-3000 (1999).
51. Grese TA, Cho S, Finley DR et al. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J. Med. Chem. 40, 146-167 (1997).
52. Saitta A, Morabito N, Frisina N et al. Cardiovascular effects of raloxifene hydrochloride. Cardiovasc. Drug Rev. 19, 57-74 (2001).
53. Mori-Abe A, Tsutsumi S, Takahashi K et al. Estrogen and raloxifene induce apoptosis by activating p38 mitogen-activated protein kinase cascade in synthetic vascular smooth muscle cells. J. Endocrinol. 178, 417-426 (2003).
54. Hochner-Celnikier D. Pharmacokinetics of raloxifene and its clinical application. Eur. J. Obstet. Gynecol. Reprod. Biol. 85, 23-29 (1999).
55. Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G. Phase II evaluation of LY-156758 in metastatic breast cancer. Oncology 45, 344-345 (1988).
56. Gradishar W, Glusman J, Lu Y, Vogel C, Cohen FJ, Sledge GW Jr. Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer 88, 2047-2053 (2000).
57. Dowsett M, Bundred NJ, Decensi A et al. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev. 10, 961-966 (2001).
58. Cauley JA, Norton L, Lippman ME et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation. Breast Cancer Res. Treat. 65, 125-134 (2001).
59. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N. Engl. J. Med. 348, 618-629 (2003).
60. Cauley JA, Martino S, Barrett-Connor E et al. Effect of raloxifene on invasive breast cancer incidence in postmenopausal women stratified by Gail risk assessment: results of the Continuing Outcomes Relevant to Evista. (CORE) trial. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 1018).
61. Martino SC, Barrett-Connor JA, Powles E et al. Incidence of invasive breast cancer following 8 years of raloxifene therapy in postmenopausal women with osteoporosis: results form the Continuing Outcomes Relevant to Evista (CORE) trial. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 1000).
62. Jordan VC, Glusman JE, Eckert S et al. Raloxifene reduces incident primary breast cancers: integrated data from multicenter, randomized, double-blind, placebo-controlled trials in postmenopausal women. Breast Cancer Res. Treat. 50 (1998) (Abstract 30).
63. Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287, 216-220 (2002).
64. Freedman M, San Martin J, O'Gorman J et al. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J. Natl Cancer Inst. 93, 51-56 (2001).
65. Jackson VP, San Martin JA, Secrest RJ et al. Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women. Am. J. Obstet. Gynecol. 188, 389-394 (2003).
66. Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, Panoulis KPC, Kelekis DA, Creatsas GC. Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause J. North Am. Menopause Soc. 9, 110-116 (2002).
67. Johnston CC Jr, Bjarnason NH, Cohen FJ et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: 3-year data from two double-blind, randomized, placebo-controlled trials. Arch. Intern. Med. 160, 3444-3450 (2000).
68. Delmas PD, Bjarnason NH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337, 1641-1647 (1997).
69. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY-139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Miner. Res. 11, 835-842 (1996).
70. Walsh BW, Kuller LH, Wild RA et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279, 1445-1451 (1998).
71. Walsh BW, Paul S, Wild RA et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol Metab. 85, 214-218 (2000).
72. Mosca L. Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial. Ann. NY Acad. Sci. 949, 181-185 (2001).
73. Vogel VG, Costantino, JP, Wickerham DL, Cronin WN. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ. Clin. Cancer Res. 9, 495S-501S (2003).
74. National Cancer Institute. Second-Year STAR Data: Enrollment Statistics. National Cancer Institute, MD, USA (2001).
75. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin. Breast Cancer 3, 153-159 (2002).
76. Gail MH, Brinton LA, Byar DP et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl Cancer Inst. 81, 1879-1886 (1989).
77. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002).
78. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291, 1701-1712 (2004).
79. Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281, 2189-2197 (1999).
80. Cohen FJ, Lu Y. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas 34, 65-73 (2000).
81. Lasco A, Gaudio A, Morabito N et al. Effects of a long-term treatment with raloxifene on insulin sensitivity in postmenopausal women. Diabetologia 47, 571-574 (2004).
82. Oleksik AM, Duong T, Pliester N, Asma G, Popp-Snijders C, Lips P. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis. J. Clin. Endocrinol. Metab. 86, 2763-2768 (2001).
83. Yaffe K, Krueger K, Sarkar S et al. Cognitive function in postmenopausal women treated with raloxifene. N. Engl. J. Med. 344, 1207-1213 (2001).
84. Chlebowski RT, Col N, Winer EP et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J. Clin. Oncol. 20, 3328-3343 (2002).
85. Zujewski J, Eng-Wong J, Reynolds J et al. A Phase 2 trial of raloxifene in premenopausal women at high risk for developing invasive breast cancer. Breast Cancer Res. Treat. 76(Suppl. 1), (2002) (Abstract 417).
86. Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer - results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98, 1802-1810 (2003).
87. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350, 1081-1092 (2004).
88. Goss P, Thomsen T, Banke-Bochita J, Lowery C, Asnis A. A randomized, placebo-controlled, explorative study to investigate the efflect of low estrogen plasma levels on markers of bone turnover in healthy postmenopausal women during the 12-week treatment with exemestane or letrozole. Breast Cancer Res. Treat. 76, 267 (2002).
89. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349, 1793-1802 (2003).
90. Cuzick J, Forbes J, Edwards R et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360, 817-824 (2002).
91. Powles T, Eeles R, Ashley S et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352, 98-101 (1998).
92. Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab. 83, 1158-1162 (1998).
93. Marttunen MB, Hietanen P, Titinen A, Roth HJ, Viinikka I, Ylikorkala O. Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer. Calcif. Tissue Int. 65, 365-368 (1999).
94. Joensuu H, Holli K, Oksanen H, Valavaara R. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res. Treat. 63, 225-234 (2000).